This trial hence supported the idea of LPL as an effective, less invasive, and safe alternative to Hartmann’s, while emphasizing the need for careful patient selection and monitoring to prevent complications such as recurrent infection or sepsis. This evidence concerns the gene LPL and Sepsis.